****When not purchasing directly from the official sales agents of the WHO, especially at online bookshops, please note that there have been issues with counterfeited copies. Buy only from known sellers and if there are quality issues, please contact the seller for a refund.***** The WHO Classification of Tumours Central Nervous System Tumours is the sixth volume in the 5th edition of the WHO series on the classification of human tumors. This series (also known as the WHO Blue Books) is regarded as the gold standard for the diagnosis of tumors and comprises a unique synthesis of histopathological diagnosis with digital and molecular pathology. These authoritative and concise reference books provide indispensable international standards for anyone involved in the care of patients with cancer or in cancer research, underpinning individual patient treatment as well as research into all aspects of cancer causation, prevention, therapy, and education. What's new in this edition? The 5th edition, guided by the WHO Classification of Tumours Editorial Board, will establish a single coherent cancer classification presented across a collection of individual volumes organized on the basis of anatomical site (digestive system, breast, soft tissue and bone, etc.) and structured in a systematic manner, with each tumor type listed within a taxonomic classification: site, category, family (class), type, and subtype. In each volume, the entities are now listed from benign to malignant and are described under an updated set of headings, including histopathology, diagnostic molecular pathology, staging, and easy-to-read essential and desirable diagnostic criteria. Who should read this book? Pathologists Neuro-oncologists Neuroradiologists Medical oncologists Radiation oncologists Neurosurgeons Oncology nurses Cancer researchers Epidemiologists Cancer registrars This volume Prepared by 199 authors and editors Contributors from around the world More than 1100 high-quality images More than 3600 references WHO Classification of Tumours Online The content of this renowned classification series is now also available in a convenient digital format by purchasing a subscription directly from IARC here.

Since the late 1960s, the survival rate in children and adolescents diagnosed with cancer has steadily improved, with a corresponding decline in the cancer-specific death rate. Although the improvements in survival are encouraging, they have come at the cost of acute, chronic, and late adverse effects precipitated by the toxicities associated with the individual or combined use of different types of treatment (e.g., surgery, radiation, chemotherapy). In some cases, the impairments resulting from cancer and its treatment are severe enough to qualify a child for U.S. Social Security Administration disability benefits. At the request of Social Security Administration, Childhood Cancer and Functional Impacts Across the Care Continuum provides current information and findings and conclusions regarding the diagnosis, treatment, and prognosis of selected childhood cancers, including different types of malignant solid tumors, and the effect of those cancers on childrenâ (TM)s health and functional capacity, including the relative levels of functional limitation typically associated with the cancers and their treatment. This report also provides a summary of selected treatments currently being studied in clinical trials and identifies any limitations on the availability of these treatments, such as whether treatments are available only in certain geographic areas.

WHO Classification of Tumours of the Central Nervous System is the revised fourth edition of the WHO series on histological and genetic typing of human tumors. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in a disease-oriented manner. Sections on all recognized neoplasms and their variants include new ICD-O codes, epidemiology, clinical features, macroscopy, pathology, genetics, and prognosis and predictive factors. The book, prepared by 122 authors from 19 countries, contains more than 800 color images and tables, and more than 2800 references. This book is in the series commonly referred to as the "Blue Book" series.

Knowledge about the etiology and diagnosis as well as treatment concepts of neu- oncologic diseases is rapidly growing. This turnover of knowledge makes it dif? cult for the physician engaged in the treatment to keep up to date with current therapies. This book sets out to close the gap and pursues several innovative concepts. As a comprehensive text on neuro-oncology, its chapters are interconnected, but at the same time some chapters or subdivisions are so thoroughly assembled that the whole volume gives the impression of several books combined into one. Neuropathology is treated in an extensive and clearly structured section. The int- ested reader ? nds for each tumor entity the latest well-referenced consensus rega- ing histologic and molecular pathology. Through this “book-in-the-book” concept, information on neuropathology is readily at hand in a concise form and without ov- loading the single chapters. Pediatric neuro-oncology differs in many entities from tumors in adult patients; also, certain tumors of the CNS are typically or mainly found only in the child. Therefore, pediatric neuro-oncology was granted its own, book-like section. Tumor entities that are treated differently in children and adults are included both in the pediatric neuro-oncology section and in the general section. Entities that typically occur only in the child and adolescent are found in the pediatric section in order to avoid redundancies.

While the first edition of this book provided a succinct introduction to pediatric neuro-oncology, biological knowledge of childhood CNS tumors has “exploded” over the past few years and a new edition of this textbook is needed to keep it up-to-date. This updated edition will include chapters on cancer predisposition in children with brain tumors, gliomas, embryonal brain tumors, ependymoma, CNS-GCT, targeted therapies in pediatric brain tumors, and long-term sequelae. New developments covered include the following: - Techniques like DNA methylation have improved the diagnostic process, and have led to an integrated diagnosis of histology, ICH and methylation. - Tumor pathways have been detected, which defines more subgroups within a tumor entity, and results in more individualized treatment for the patient. - Therapeutic options outside the standard combination of surgery, chemotherapy, and radiation have either been implemented within the last years, or are currently under consideration. This book will be aimed at pediatric oncologists and neurooncologists, neurosurgeons, radiation oncologists. Chapters detailing quality of life and supportive care will make this 2nd edition a useful resource for nurses, social workers, physiotherapists, and occupational therapists alike.